AN2 Therapeutics, Inc. Operating Income
AN2 Therapeutics, Inc. (ANTX) reported Operating Income of -$8.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- AN2 Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$8.90M.
- AN2 Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$10.55M.
- AN2 Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$9.32M.
- AN2 Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$10.04M.
- AN2 Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$38.11M.
- AN2 Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$56.79M.
- AN2 Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$69.64M.
- AN2 Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$42.26M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.90M 10-Q · filed 2026-08-11 | -$19.45M 10-Q · filed 2026-08-11 | -$28.77M derived: sum of 3 quarters · filed 2026-08-11 | -$38.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$10.55M 10-Q · filed 2026-05-11 | -$19.87M derived: sum of 2 quarters · filed 2026-05-11 | -$29.91M derived: sum of 3 quarters · filed 2026-05-11 | -$37.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$9.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$19.36M derived: sum of 2 quarters · filed 2026-03-17 | -$26.57M derived: sum of 3 quarters · filed 2026-08-11 | -$38.11M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$10.04M 10-Q · filed 2025-11-12 | -$17.26M derived: sum of 2 quarters · filed 2026-08-11 | -$28.79M 10-Q · filed 2025-11-12 | -$37.39M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$7.22M 10-Q · filed 2026-08-11 | -$18.75M 10-Q · filed 2026-08-11 | -$27.35M derived: sum of 3 quarters · filed 2026-08-11 | -$41.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$11.54M 10-Q · filed 2026-05-11 | -$20.14M derived: sum of 2 quarters · filed 2026-05-11 | -$34.15M derived: sum of 3 quarters · filed 2026-05-11 | -$50.03M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$22.61M derived: sum of 2 quarters · filed 2026-03-17 | -$38.49M derived: sum of 3 quarters · filed 2026-03-17 | -$56.79M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$14.01M 10-Q · filed 2025-11-12 | -$29.89M derived: sum of 2 quarters · filed 2025-11-12 | -$48.19M 10-Q · filed 2025-11-12 | -$67.00M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$15.88M 10-Q · filed 2025-08-12 | -$34.18M 10-Q · filed 2025-08-12 | -$52.99M derived: sum of 3 quarters · filed 2025-08-12 | -$71.17M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$18.30M 10-Q · filed 2025-05-13 | -$37.11M derived: sum of 2 quarters · filed 2025-05-13 | -$55.29M derived: sum of 3 quarters · filed 2025-05-13 | -$71.89M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$18.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$36.99M derived: sum of 2 quarters · filed 2025-03-25 | -$53.60M derived: sum of 3 quarters · filed 2025-03-25 | -$69.64M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$18.18M 10-Q · filed 2024-11-13 | -$34.78M derived: sum of 2 quarters · filed 2024-11-13 | -$50.82M 10-Q · filed 2024-11-13 | -$63.30M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$16.60M 10-Q · filed 2024-08-13 | -$32.64M 10-Q · filed 2024-08-13 | -$45.12M derived: sum of 3 quarters · filed 2024-08-13 | -$56.89M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$16.04M 10-Q · filed 2024-05-14 | -$28.52M derived: sum of 2 quarters · filed 2024-05-14 | -$40.28M derived: sum of 3 quarters · filed 2024-05-14 | -$50.62M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$12.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$24.25M derived: sum of 2 quarters · filed 2024-03-29 | -$34.58M derived: sum of 3 quarters · filed 2024-03-29 | -$42.26M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$11.77M 10-Q · filed 2023-11-09 | -$22.10M derived: sum of 2 quarters · filed 2023-11-09 | -$29.79M 10-Q · filed 2023-11-09 | -$37.38M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$10.33M 10-Q · filed 2023-08-10 | -$18.02M 10-Q · filed 2023-08-10 | -$25.61M derived: sum of 3 quarters · filed 2023-08-10 | -$32.54M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$7.68M 10-Q · filed 2023-05-11 | -$15.28M derived: sum of 2 quarters · filed 2023-05-11 | -$22.21M derived: sum of 3 quarters · filed 2023-05-11 | -$27.21M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$7.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | -$14.53M derived: sum of 2 quarters · filed 2023-03-29 | -$19.52M derived: sum of 3 quarters · filed 2023-03-29 | -$21.57M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$6.93M 10-Q · filed 2022-11-09 | -$11.93M derived: sum of 2 quarters · filed 2022-11-09 | -$13.98M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | -$5.00M 10-Q · filed 2022-08-11 | -$7.05M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$2.05M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |